NBIX
A quarter that didn’t phone it in
Neurocrine came out swinging in Q1 2026, reporting $811.0 million in net product sales — a 44% jump from a year ago. That’s the kind of number that makes you sit up a little straighter, especially in a biotech world where “solid execution” can sometimes mean “we didn’t trip over our own shoelaces.”
The Soleno plot twist
The company also announced a definitive agreement to acquire Soleno Therapeutics, bringing VYKAT TM XR (diazoxide choline) into the fold for treating hyperphagia in Prader-Willi syndrome. The deal is expected to close in Q2 2026, which means this isn’t just a pipeline story anymore — Neurocrine is trying to buy more runway instead of waiting for it.
Pipeline plus backbone
On top of the M&A headline, Neurocrine started a Phase 2 study of NBI-1117570, its dual M1/M4 selective agonist, in adults with schizophrenia. That’s the company saying, in effect: the commercial engine is working, but we’re also still betting on future shots on goal.
Meanwhile, management reaffirmed its 2026 full-year INGREZZA net sales guidance of $2.7 billion to $2.8 billion. So if you’re holding the stock, the message is pretty clear: the current business is humming, and the company still believes its core franchise has plenty of juice left.
Big picture: Neurocrine’s quarter reads like a growth-stock checklist — strong sales, more pipeline progress, and a bolt-on acquisition to widen the moat. Investors usually like it when the story isn’t just about one drug doing all the heavy lifting.